Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ111711220,54
KB106810700,47
PKN67,9367,9-0,73
Msft7,63
Nokia4,3854,451,06
IBM-0,89
Mercedes-Benz Group AG52,6252,65-2,73
PFE-1,97
02.05.2025 9:00:58
Indexy online
AD Index online
select
AD Index online
 

  • 30.04.2025 18:00:12
MABION (MABP.WA, Warsaw)
Poslední obchod Změna (%) Změna (PLN) Objem obchodů (PLN)
10,92 -2,15 -0,24 394 165
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.05.2025
Popis společnosti
Obecné informace
Název společnostiMabion SA
TickerMAB
Kmenové akcie:Ordinary Shares
RICMABP.WA
ISINPLMBION00016
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 226
Akcie v oběhu k 30.09.2024 16 162 326
MěnaPLN
Kontaktní informace
Ulicegen. Mariana Langiewicza 60
MěstoKONSTANTYNOW LODZKI
PSČ95-050
ZeměPoland
Kontatní osobaMichal Wierzchowski
Funkce kontaktní osobyIR Contact Officer
Telefon48 422 077 890
Fax48422032703
Kontatní telefon48 531 613 067

Business Summary: Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Mabion SA revenues decreased 39% to PLN64.3M. Net income decreased 73% to PLN11.5M. Revenues reflect Sale of Products decrease of 38% to PLN62.1M, Sales of Materials decrease of 71% to PLN702K, Leasing decrease of 36% to PLN1.5M. Net income also reflects General/Admin. Expense increase of 45% to PLN43.1M (expense), Interest Expense increase from PLN46K to PLN2.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 02.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Supervisory BoardRobert Konski5823.06.202323.06.2023
President of the Management Board, Chief Executive OfficerKrzysztof Kaczmarczyk4814.05.202116.03.2020
Independent Deputy Chairman of the Supervisory BoardJozef Banach-23.06.2023
Chief Financial Officer, Member of the Management BoardGrzegorz Grabowicz-02.01.201902.01.2019
Chief Operating Officer, Member of the Management BoardJulita Balcerek-08.11.202308.11.2023
Head of Business Development, Chief Commercial Officer, Member of the Management BoardAdam Pietruszkiewicza-25.01.2021